Pepscan appoints chief business officer

Michiel Lodder joins the Dutch firm from OctoPlus

Pepscan Therapeutics, a Dutch biotech company focused on protein mimicry for the discovery of therapeutics peptides and antibodies, has appointed Michiel Lodder as chief business officer.

Lodder joins the firm from OctoPlus, where he was senior manager business development, responsible for licensing, partnering, and alliance management activities.

Pepscan has recently established a number of research collaboration and licensing agreements with major pharma and biotech companies, and Lodder’s experience is expected to enable the firm to add to these partnerships.

You may also like

Research & Development

Pepscan Therapeutics signs agreement with Crucell

Partners aim to develop of novel vaccines to combat infectious diseases
Research & Development

Pepscan agrees research collaboration with Tibotec

Will use CLIPS to develop therapeutic peptides
Research & Development

Immunovo secures seed funding from venture capitalists

Signs partnering agreement with Pepscan, which takes minority interest in Immunovo
Pharmaceutical

PharmNovo enhances its board ahead of Phase II development

The new board members bring complementary experience in drug development, clinical execution and partnering, supporting the company’s continued progress and dialogue with potential partners
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Pharmaceutical

New research suggests repurposed diabetic drug may help prostate cancer

A class of medication called SGLT2 inhibitors, traditionally used for diabetes, may help slow prostate cancer progression in men receiving hormone treatment
Drug Delivery

Indonesia looks to oral GLP-1s as it battles rising obesity

Novo Nordisk's oral GLP-1 therapy for chronic weight management could help the country deliver injectable-comparable weight loss alongside cardiovascular risk-reduction benefits for its expanding population
Subscribe now